Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization.
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results - read this article along with other careers information, tips and advice on BioSpace
Published: May 10, 2021
Galafold® (migalastat) PerformanceReflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M
1Q21 Total Galafold Revenue of $66.4M Driven by Continued Global Growth
Positive Pre-BLA Meeting Held with U.S. FDA for AT-GAA in Pompe Disease; Rolling BLA Submission On-Track for Completion in 2Q21with Global Submissions Expected Throughout 2021
New Data from Pompe and Fabry Gene Therapy Programs to be Presented at American Society of Gene & Cell Therapy 24th Annual Meeting May 11th-14th
Continue to Strengthen Senior Management Team with Addition of Sébastien Martel as SVP, Strategy & Business Development